# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE:PM), today announces the sale of its ...
UBS analyst Nik Oliver maintains Philip Morris Intl (NYSE:PM) with a Sell and raises the price target from $95 to $105.
Barclays analyst Gaurav Jain maintains Philip Morris Intl (NYSE:PM) with a Overweight and raises the price target from $130 ...
Stifel analyst Matthew Smith maintains Philip Morris Intl (NYSE:PM) with a Buy and raises the price target from $120 to $138.